<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748202</url>
  </required_header>
  <id_info>
    <org_study_id>CE1145_1001</org_study_id>
    <nct_id>NCT00748202</nct_id>
  </id_info>
  <brief_title>Berinert P Study of Subcutaneous Versus Intravenous Administration</brief_title>
  <acronym>PASSION</acronym>
  <official_title>Pharmacokinetics Berinert P Study of Subcutaneous Versus Intravenous Administration in Subjects With Moderate Hereditary Angioedema - The Passion Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical trial center Rhine-Main</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZKI Kindergerinnungslabor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut f√ºr Medizinische Virologie JWG-University hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PharmaPart</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.)&#xD;
      administration of Berinert P in patients with hereditary angioedema (HAE) to establish a&#xD;
      second administration mode in cases where i.v. access is not suitable.&#xD;
&#xD;
      The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic&#xD;
      study.&#xD;
&#xD;
      Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert&#xD;
      P) and than switch to the treatment not administered before.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hereditary angioedema (HAE), suffer from recurring and mostly unforeseeable&#xD;
      attacks of acute oedema of subcutaneous tissues of various organs. The pathophysiological&#xD;
      correlate of this disease is a deficiency in functionally active C1-Esterase Inhibitor&#xD;
      (C1-INH). Today, two main types of HAE are described. In HAE type I, an impaired synthesis&#xD;
      and an elevated turnover of a normal and functional active C1-INH molecule takes place,&#xD;
      causing reduced amounts in functionally active C1-INH. In HAE type II, normal levels of a&#xD;
      functionally impaired C1-INH molecule are synthesized. Both defects are inherited as an&#xD;
      autosomal dominant trait. HAE type III is limited to females and not associated with C1-INH&#xD;
      deficiency; the pathophysiology of this type remains to be determined. Corticosteroids,&#xD;
      antihistamines or epinephrine usually do not exert any positive effect in acute attacks&#xD;
      caused by HAE. This is of particular importance as these types of medication are often used&#xD;
      in case of oedema in general. In case of acute oedema in patients suffering from HAE, the&#xD;
      intravenous administration of C1-INH concentrate (e.g., Berinert P) is the treatment of&#xD;
      choice. The study is performed to investigate the s.c. versus i.v. administration of Berinert&#xD;
      P in patients with hereditary angioedema (HAE) to establish a second administration mode in&#xD;
      cases where i.v. access is not suitable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual courses of C1-inhibitor levels, from these will be derived pharmacokinetic parameters</measure>
    <time_frame>i.v. and s.c.samples: 0, 0.25, 0.5, 0.75 hours and 1, 2, 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 120, 168, 336 an 504 hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of s.c. and i.v. administration of study medication</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1-Esterase Inhibitor</intervention_name>
    <description>1000 I.E.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Berinert P</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with an established diagnosis of HAE type I (C1-Inhibitor activity &lt; 50% and&#xD;
             C1-Inhibitor antigen &lt; 15.4 mg/dl) or HAE type II (C1-Inhibitor activity &lt; 50% and&#xD;
             C1-Inhibitor antigen in normal or elevated concentration of dysfunctional protein).&#xD;
&#xD;
          -  Male and female subjects with an age of at least 18 years.&#xD;
&#xD;
          -  Subjects providing an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects without an established diagnosis of HAE.&#xD;
&#xD;
          -  Last C1-INH administration less than 7 days ago and/or acute attack.&#xD;
&#xD;
          -  Subjects with acquired angioedema (AAE).&#xD;
&#xD;
          -  All other types of angioedema not associated with C1-INH deficiency.&#xD;
&#xD;
          -  Treatment with any investigational drug (exclusive drugs appropriate for the treatment&#xD;
             of acute angioedema) 30 days before study treatment.&#xD;
&#xD;
          -  Treatment with any other drug appropriate for the treatment of acute angioedema within&#xD;
             7 days before start of study treatment at each phase.&#xD;
&#xD;
          -  Danazol prophylaxis.&#xD;
&#xD;
          -  Prophylaxis with antifibrinolytics, EACA, tranexamic acid.&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to study medication (Berinert P).&#xD;
&#xD;
          -  Pregnant women (pregnancy rapid assay required for women with childbearing potential),&#xD;
             women currently breast-feeding, or with the intention to breast-feed&#xD;
&#xD;
          -  Subjects with malignant diseases.&#xD;
&#xD;
          -  Subjects with immunodeficiencies such as established acquired immunodeficiency&#xD;
             syndrome.&#xD;
&#xD;
          -  Subjects with concurrent serious or acute illness or infection as per investigators&#xD;
             judgement.&#xD;
&#xD;
          -  Subjects with mental conditions which render the subject or its legally acceptable&#xD;
             representative unable to understand the nature, scope and possible consequences of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfhart Kreuz, PD Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre of Paediatrics III, Department of Haematology, Haemostaseology and Oncology, Comprehensive Care Centre for Thrombosis and Haemostasis, Johann-Wolfgang-Goethe-University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre of Paediatrics III, Department of Haematology, Haemostaseology and Oncology, Comprehensive Care Centre for Thrombosis and Haemostasis, Johann-Wolfgang-Goethe-University Hospital</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Wolfhart Kreuz</name_title>
    <organization>Centre of Paediatrics III, Department of Haematology, Haemostaseology and Oncology, Comprehensive Care Centre for Thrombosis and Haemostasis</organization>
  </responsible_party>
  <keyword>Hereditary angioedema</keyword>
  <keyword>C1-Esterase inhibitor</keyword>
  <keyword>intravenous</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

